Clinical Perspectives
In patients with severe MR, RV dysfunction is associated with increased adverse outcomes. TAPSE was an independent predictor of CV events following MitraClip therapy. Its cut-off value (11%) may be independently available to predict CV events following MitraClip therapy. The present study comprised a small sample size and focused on short-term results. Properly designed trials with longer follow-up and more patients are required to confirm our results.